Streetbeat News

Regulatory

CNSP

CNS Pharmaceuticals shares are trading higher following the company's request for a panel hearing on November 5, 2024. The decision on suspension or delisting will be on hold until the hearing.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 1:15 pm

SPY

Federal Reserve Governor Michelle Bowman did not provide any comments on the economic or monetary policy outlook during her introductory remarks at the Philly Fed Fintech Conference.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 1:08 pm

ARKB

FETH

IBIT

Bitcoin spot ETFs experienced a $79 million outflow after a week of inflows, with mixed results among different funds. BlackRock's ETF gained $42.9 million, while ARK Invest's ETF saw a $134.7 million outflow. Ethereum spot ETFs showed resilience with a $11.9 million inflow, led by Fidelity's ETF. Bitcoin futures market shows signs of caution, with decreased funding rates and plateauing volumes. The upcoming U.S. elections and economic indicators are influencing market sentiment.

Portfolio Pulse from Murtuza Merchant

October 23, 2024 | 1:01 pm

MCD

The CDC, FDA, and USDA-FSIS are investigating a multistate E. coli outbreak linked to McDonald's Quarter Pounder hamburgers. Early FDA information suggests onions may be a source of contamination.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:43 pm

FAMI

Farmmi has been granted an extension by Nasdaq to meet the minimum bid price requirement, allowing the company more time to comply with listing standards.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:37 pm

APRE

Aprea Therapeutics presented preliminary findings on its oral WEE1 inhibitor, APR-1051, at an international conference. The Phase 1 trial shows APR-1051 is safe and well-tolerated with no hematologic toxicity. The study is ongoing with active enrollment in the U.S.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:35 pm

CELU

Celularity has filed an appeal request and an amended compliance plan with Nasdaq. This move is likely in response to a notice of non-compliance with Nasdaq's listing requirements.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:34 pm

ICU

SeaStar Medical Holding Corporation (NASDAQ:ICU) has announced that Stanford Medicine is cleared to enroll subjects in the NEUTRALIZE-AKI pivotal trial for adult acute kidney injury. This trial now includes 12 sites with 52 subjects enrolled.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:30 pm

CNSP

CNS Pharmaceuticals has requested a hearing with a panel on November 5, 2024, to halt the suspension or delisting of its stock pending a decision.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:16 pm

JSPR

Jasper Therapeutics (NASDAQ:JSPR) is starting an open-label extension study for chronic urticarias, rolling over patients from the BEACON and SPOTLIGHT studies. They have regulatory clearance to expand the BEACON study with a new 360mg dose cohort, with data expected in early 2025.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:15 pm